. 2020 Jan 3;69(3):383–397. doi: 10.1007/s00262-019-02456-z

Table 3.

Patient distribution around the cutoffs identified for immune biomarker parameters in the two study arms

Immune biomarker	Cutoff value	SOC + Oregovomab arm (n^a/n^b, %^c)	SOC arm (n^a/n^b, %^c)	p value^d
Change in the number of CA125-specific IFN-γ⁺CD8⁺ T lymphocytes/ml	≥ 6.69x10³	9/3, 75.0	4/11, 26.7	0.013
Number of MDSC4/ml	≥ 137,300	10/13, 43.5	10/14, 41.7	n.s.
NMLR	≥ 4.388	10/26, 27.8	8/27, 22.9	n.s.

n.s.: not statistically significant

^aNumber of patients with parameter value above cutoff

^bNumber of patients with parameter value below cutoff

^cPercentage of patients with parameter value above cutoff

^dBy Fisher’s exact test